628 related articles for article (PubMed ID: 19458065)
21. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
[TBL] [Abstract][Full Text] [Related]
22. Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
van Nimwegen MJ; Verkoeijen S; van Buren L; Burg D; van de Water B
Cancer Res; 2005 Jun; 65(11):4698-706. PubMed ID: 15930288
[TBL] [Abstract][Full Text] [Related]
23. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
24. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma.
Masuda T; Wada K; Nakajima A; Okura M; Kudo C; Kadowaki T; Kogo M; Kamisaki Y
Clin Cancer Res; 2005 Jun; 11(11):4012-21. PubMed ID: 15930335
[TBL] [Abstract][Full Text] [Related]
25. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
26. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
Williams CR; Tabios R; Linehan WM; Neckers L
J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057
[TBL] [Abstract][Full Text] [Related]
27. Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells.
Earley S; Plopper GE
Biochem Biophys Res Commun; 2006 Nov; 350(2):405-12. PubMed ID: 17010315
[TBL] [Abstract][Full Text] [Related]
28. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
[TBL] [Abstract][Full Text] [Related]
29. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
30. In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.
Ochel HJ; Gademann G
Anticancer Res; 2006; 26(3A):2085-91. PubMed ID: 16827149
[TBL] [Abstract][Full Text] [Related]
31. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
32. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
Erlichman C
Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
[TBL] [Abstract][Full Text] [Related]
33. Focal adhesion kinase promotes the aggressive melanoma phenotype.
Hess AR; Postovit LM; Margaryan NV; Seftor EA; Schneider GB; Seftor RE; Nickoloff BJ; Hendrix MJ
Cancer Res; 2005 Nov; 65(21):9851-60. PubMed ID: 16267008
[TBL] [Abstract][Full Text] [Related]
34. Focal adhesion kinase: a potential target in cancer therapy.
van Nimwegen MJ; van de Water B
Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283
[TBL] [Abstract][Full Text] [Related]
35. Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells.
van Nimwegen MJ; Huigsloot M; Camier A; Tijdens IB; van de Water B
Mol Pharmacol; 2006 Oct; 70(4):1330-9. PubMed ID: 16825486
[TBL] [Abstract][Full Text] [Related]
36. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Agochiya M; Brunton VG; Owens DW; Parkinson EK; Paraskeva C; Keith WN; Frame MC
Oncogene; 1999 Oct; 18(41):5646-53. PubMed ID: 10523844
[TBL] [Abstract][Full Text] [Related]
37. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Hehlgans S; Lange I; Eke I; Cordes N
Radiother Oncol; 2009 Sep; 92(3):371-8. PubMed ID: 19729215
[TBL] [Abstract][Full Text] [Related]
38. Potent triazolothione inhibitor of heat-shock protein-90.
Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B
Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743
[TBL] [Abstract][Full Text] [Related]
39. High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin.
Lukasiewicz E; Miekus K; Kijowski J; Gozdzik J; Wilusz M; Bobis-Wozowicz S; Wiecha O; Majka M
J Physiol Pharmacol; 2009 Sep; 60(3):161-6. PubMed ID: 19826195
[TBL] [Abstract][Full Text] [Related]
40. Focal adhesion kinase in neutrophil-induced microvascular hyperpermeability.
Guo M; Wu MH; Granger HJ; Yuan SY
Microcirculation; 2005 Mar; 12(2):223-32. PubMed ID: 15824042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
